Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* At increased risk for breast cancer, as defined by 1 of the following criteria:~  * Histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only~ * Composite increased breast cancer risk of ≥ 1.67% over 5 years, based on the following criteria:~    * Age~   * Number of first-degree female relatives with breast cancer~   * One or more prior breast biopsies~      * Fine-needle aspiration cytology of a non-cystic lesion in lieu of an open biopsy is considered a biopsy~   * Prior diagnosis of atypical hyperplasia of the breast~   * Age at first live birth~   * Nulliparity~   * Race~   * Age at onset of menarche~* No prior or suspected invasive breast cancer or ductal carcinoma in situ~* No clinical evidence of malignancy by physical examination, including a breast examination within the past 3 months~* No evidence of suspicious or malignant disease or uncharacterized lesions on bilateral mammogram within the past 6 months~* Normal gynecologic examination, including a bimanual pelvic examination and, if indicated, pap smear within the past 12 months~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 35 and over~Sex~* Female~Menopausal status~* Premenopausal and ovulating\*, defined as having regular menses for the past 6 months OR irregular menses with follicular phase (i.e., day 3) follicle-stimulating hormone level \< 20 mIU/mL OR~* Postmenopausal NOTE: \* Ovulation is determined by day 21 progesterone level \> 3 ng/mL~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Complete blood count normal~* No active bleeding disorder (e.g., qualitative or quantitative platelet abnormality, hemophilia, or von Willebrand's disease)~Hepatic~* Liver function tests normal~Renal~* Not specified~Cardiovascular~* No prior deep-vein thrombosis except a single occurrence related to lower extremity trauma~* No prior cerebral vascular accident~* No prior transient ischemic attack~Pulmonary~* No prior pulmonary embolus except a single occurrence related to lower extremity trauma~Other~* No saline or silicone breast implants~* No known allergy to tamoxifen~* No macular degeneration~* No malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No nonmalignant disease that would preclude administration of tamoxifen~* No psychiatric condition, including a history of clinical depression or addictive disorder, that would preclude giving informed consent or study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective nonhormonal contraception during and for 3 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior systemic adjuvant chemotherapy for LCIS~Endocrine therapy~* No prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators~* At least 3 months since prior and no concurrent use of any of the following drugs:~  * Estrogen or progesterone replacement therapy~ * Oral contraceptives~ * Androgens~ * Luteinizing hormone-releasing hormone analogs~ * Prolactin inhibitors~ * Antiandrogens~ * Steroids~* No concurrent steroids for asthma~Radiotherapy~* No prior radiotherapy for LCIS~Surgery~* No prior bilateral prophylactic mastectomy~* No prior mastectomy for LCIS~Other~* Concurrent nonhormonal medications allowed~* No concurrent warfarin or cholestyramine~* No prior or concurrent participation in any other cancer prevention study~  * Patients treated with placebo on protocol NSABP-P-1 are eligible

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).